Asian Currencies Stay Rangebound as Yen Firms on Intervention Talk 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Nikkei 225 Hits Record High Above 56,000 After Japan Election Boosts Market Confidence 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Jerome Powell Attends Supreme Court Hearing on Trump Effort to Fire Fed Governor, Calling It Historic 
Fifty-seven lawsuits alleging that hair relaxer products sold by L'Oreal USA Inc and two India-based firms cause cancer and other health problems will be consolidated before US District Judge Mary Rowland in Chicago,
The Chicago federal court will streamline discovery efforts and other pretrial issues for the cases, according to the order.
The lawsuits, which have been filed in federal courts across the country, alleged that the companies knew about the dangerous chemicals in their products but marketed and sold them anyway.
The cases name the US subsidiary of L'Oreal SA and subsidiaries of India-based companies Godrej SON Holdings Inc. and Dabur International Ltd.
Representatives for the companies opposed the centralization of the cases.
L'Oreal said it is confident in the safety of its products and that lawsuits against it have no legal merit.
The claims come in response to a National Institutes of Health research that was published in October and revealed that women who used the products frequently had a greater than doubled risk of developing uterine cancer.
The panel's decision, according to Diandra Debrosse Zimmermann of DiCello Levitt, who filed the initial case after the study's publication, "recognized the clear benefits of centralizing the hair relaxer litigation," and she anticipates that many more companies will do the same in the upcoming weeks.
As the goods are often promoted to women of color, Zimmermann expects hundreds of women may end up suing over them.
